PVX 108

Drug Profile

PVX 108

Alternative Names: Peanut allergy vaccine - Aravax; PVX108

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator Aravax
  • Class Peptides; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Peanut hypersensitivity

Most Recent Events

  • 10 May 2017 Phase-I clinical trials in Peanut hypersensitivity (Prevention) in Australia (Intradermal) (ACTRN12617000692336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top